---
title: "PTPRD"
date: 2023-05-15 00:00:00
layout: post
categories: Gene
summary: "## Gene Information"
tags: ['PTPRD', 'tyrosinephosphatase', 'cancer', 'tumorsuppressor', 'immunotherapy', 'somaticmutations', 'drugresponse', 'prognosis']
---

## Gene Information

Gene Name: PTPRD (protein tyrosine phosphatase, receptor type D)  
Genomic Location: Chromosome 9 (9p23)  
Aliases: PTPRD1, PTP-SL, R-PTP-D, RPTPDELTA  

## Function

PTPRD encodes a receptor-type protein tyrosine phosphatase. It plays a role in cell-cell signaling and neuronal development, as well as in cancer suppression. PTPRD regulates the phosphorylation of target proteins by dephosphorylating tyrosine residues.

## External IDs and Sites

- HGNC: 9632
- NCBI Entrez: 5789
- Ensembl: ENSG00000147852
- OMIM: 179947
- UniProtKB/Swiss-Prot: Q12923

## Mutations

### AA Mutation List with dbSNP ID

|AA Mutation|Mutation Type|dbSNP ID|
|---|---|---|
|G1352R|Missense|rs61750900|
|Q711E|Missense|rs35871469|
|R1233C|Missense|rs786205097|
|R1486H|Missense|rs1554111806|
|S1509N|Missense|rs34064118|
|H1602Y|Missense|rs755916642|
|W1682C|Missense|rs1554550154|

## Somatic Mutations

### SNVs/Insertions/Deletions with dbSNP ID

|Mutation Type|dbSNP ID|
|---|---|
|Missense|rs863224215|
|Frameshift|rs774952314|
|Frameshift|rs779176331|
|Splice Site|rs786205070|

## Related Diseases

- Colorectal cancer
- Glioblastoma
- Lung adenocarcinoma
- Breast cancer
- Hepatocellular carcinoma
- Acute myeloid leukemia
  
## Treatment and Prognosis

PTPRD is a potential therapeutic target for cancer. Its loss of expression or function has been associated with tumorigenesis, tumor cell growth, and metastasis.

## Drug Response

Studies suggest that pharmacological inhibition of PTPRD activity could be a strategy for enhancing immune cell function and antitumor immunity.

## References

- Pan Y, Jensen P, Dakshnamurthy S, et al. (2008). "The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers". Proc. Natl. Acad. Sci. U.S.A. 105 (38): 14182–7. 
- LaMontagne K, Littlewood-Evans A, Schnell C, et al. (May 2016). "Antagonism of the phosphatase PTPRJ delays leukemia initiation and extends survival". Proc. Natl. Acad. Sci. U.S.A. 113 (27): 7606–11. 
- Wang SY, Yeh YA, Jiang X, et al. (December 2016). "Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy". Mol. Cancer Ther. 15 (12): 2593–2601.

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**